Tralokinumab’s role in AD management derives from its inhibition of IL-13 binding to IL-13 receptor, thereby attenuating downstream inflammatory signaling pathways implicated in skin barrier dysfunction and pruritus [15]. Here, IL13 is linked to Alzheimer disease.